Risk of solid cancer in low dose-rate radiation epidemiological studies and the dose-rate effectiveness factor
- 15 May 2017
- journal article
- research article
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 93 (10) , 1064-1078
Abstract
Purpose: Estimated radiation risks used for radiation protection purposes have been based primarily on the Life Span Study (LSS) of atomic bomb survivors who received brief exposures at high dose rates, many with high doses. Information is needed regarding radiation risks from low dose-rate (LDR) exposures to low linear-energy-transfer (low-LET) radiation. We conducted a meta-analysis of LDR epidemiologic studies that provide dose-response estimates of total solid cancer risk in adulthood in comparison to corresponding LSS risks, in order to estimate a dose rate effectiveness factor (DREF). Materials and methods: We identified 22 LDR studies with dose-response risk estimates for solid cancer after minimizing information overlap. For each study, a parallel risk estimate was derived from the LSS risk model using matching values for sex, mean ages at first exposure and attained age, targeted cancer types, and accounting for type of dosimetric assessment. For each LDR study, a ratio of the excess relative risk per Gy (ERR Gy−1) to the matching LSS ERR risk estimate (LDR/LSS) was calculated, and a meta-analysis of the risk ratios was conducted. The reciprocal of the resultant risk ratio provided an estimate of the DREF. Results: The meta-analysis showed a LDR/LSS risk ratio of 0.36 (95% confidence interval [CI] 0.14, 0.57) for the 19 studies of solid cancer mortality and 0.33 (95% CI 0.13, 0.54) when three cohorts with only incidence data also were added, implying a DREF with values around 3, but statistically compatible with 2. However, the analyses were highly dominated by the Mayak worker study. When the Mayak study was excluded the LDR/LSS risk ratios increased: 1.12 (95% CI 0.40, 1.84) for mortality and 0.54 (95% CI 0.09, 0.99) for mortality + incidence, implying a lower DREF in the range of 1–2. Meta-analyses that included only cohorts in which the mean dose was <100 mGy yielded a risk ratio of 1.06 (95% CI 0.30, 1.83) for solid cancer mortality and 0.58 (95% CI 0.10, 1.06) for mortality + incidence data. Conclusions: The interpretation of a best estimate for a value of the DREF depends on the appropriateness of including the Mayak study. This study indicates a range of uncertainty in the value of DREF between 1 and about 2 after protracted radiation exposure. The LDR data provide direct evidence regarding risk from exposures at low dose rates as an important complement to the LSS risk estimates used for radiation protection purposes.Keywords
This publication has 68 references indexed in Scilit:
- Random-Effects Meta-analysis of Inconsistent Effects: A Time for ChangeAnnals of Internal Medicine, 2014
- Cancer Risk Associated with Low-dose and Low-dose-rate Ionizing Radiation ExposureGenes and Environment, 2013
- The third analysis of cancer mortality among Japanese nuclear workers, 1991–2002: estimation of excess relative risk per radiation doseJournal of Radiological Protection, 2012
- Updated Mortality Analysis of Radiation Workers at Rocketdyne (Atomics International), 1948–2008Radiation Research, 2011
- The 15-Country Collaborative Study of Cancer Risk among Radiation Workers in the Nuclear Industry: Estimates of Radiation-Related Cancer RisksRadiation Research, 2007
- Radiation Exposure due to Local Fallout from Soviet Atmospheric Nuclear Weapons Testing in Kazakhstan: Solid Cancer Mortality in the Semipalatinsk Historical Cohort, 1960–1999Radiation Research, 2005
- Cancer Incidence Among Finnish Nuclear Reactor WorkersJournal of Occupational and Environmental Medicine, 2002
- 100 years of observation on British radiologists: mortality from cancer and other causes 1897–1997British Journal of Radiology, 2001
- First Analysis of Mortality and Occupational Radiation Exposure based on the National Dose Registry of CanadaAmerican Journal of Epidemiology, 1998
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986